Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces the company has been approved for its planned pediatric study from the Pediatric Committee of EMA, European Medicines Agency, (PDCO).
Regulatory
In the previously announced press release the following text was included: This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure…
Regulatory
Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 22, 2018, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes t…
Regulatory
Strong development towards our strategic objectives
Non-regulatory
Sedana Medical AB (publ) (Sedana Medical or the company) presents a health economic analysis at the European Conference for Health Economics and Outcomes Research 2018 (ISPOR) in Barcelona, showing clinical and economic benefits of inhaled isoflurane…
Regulatory
Sedana Medical AB (publ) (Sedana Medical or the company) announces today that the company has received market approval for AnaConDa from the Ministry of Health, Labour and Welfare (MHLW) in Japan. Through the approval, AnaConDa can now be marketed,…
Non-regulatory
Sedana Medical AB (publ) (Sedana Medical or Company) has established its own sales organization in Great Britain, in accordance with the previously announced plan. The Company is now delivering its first direct deliveries of AnaConDa for sedation of…
Regulatory
Sedana Medical AB (publ) (“Sedana Medical”) broadens the shareholder base through a secondary sale of existing shares by four insiders to Handelsbanken Fonder, Apus Capital, Norron Asset Management and Brohuvudet AB (the “Block Sale”). The Block Sale…
Regulatory
In the press release published 30 August 07:00 CET the following has been reported: · EBITDA amounted to 1 794 (1 081) KSEK and the EBITDA margin was -6,0% (5,6%). Correct reporting is: · EBITDA amounted to -1 794 (1 081) KSEK and the EB…
Regulatory
The registration process for the United States commenced and European study resumed at full speed
Non-regulatory
On August 30, 2018, at 07:00 am CET, Sedana Medical AB (publ) (Sedana Medical or the Company) will publish its interim report for the second quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which wil…
Regulatory
Sedana Medical AB (publ) (Sedana Medical or the Company) announces today that the Company has received approval from the central ethical committee for its pivotal phase 3-study in Germany, IsoConDa, to continue to use the original study protocol afte…
Regulatory
Sedana Medical AB (publ), developing and marketing the medical device AnaConda and volatile anesthetics for sedation of mechanically ventilated intensive care unit (ICU) patients, today announced the recruitment of Gunilla Mickelsson as Global Market…
Regulatory
Sedana Medical AB (publ) (”Sedana Medical” or the ”Company”), today announces that the Company has successfully completed a directed new share issue of approximately SEK 112 million.
Regulatory
Sedana Medical AB (publ) (”Sedana Medical” or the ”Company”) today announces its intention to execute a directed new share issue to Swedish and international investors (the ”Private Placement”). The Company has appointed Pareto Securities AB (”Pareto…
Regulatory
Sedana Medical AB (publ) held the annual general meeting on 22 May 2018 in Stockholm. Below follows a summary of the resolutions that were made during the meeting.
Non-regulatory
On May 22, 2018, at 12:30 pm CET, Sedana Medical AB (publ) (Sedana Medical or the Company) will publish its interim report for the first quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which will in…
Regulatory
Sedana Medical´s Annual Report for 2017 has been published and is available on www.sedanamedical.com.
Regulatory
Sedana Medical AB ("Sedana Medical or the Company") reports a more than expected 60% increase in sales in the first quarter of 2018 compared to the corresponding period in 2017.